Real world outcomes in patients with Philadelphia chromosome positive acute lymphoblastic leukemia undergoing allogeneic stem cell transplantation–A single institution experience

•Duration, type and timing of TKI remains controversial for Ph+ ALL.•Pre-transplant dasatinib/imatinib led to favorable outcomes among Ph+ ALL patients.•Type of pre-transplant TKI did not impact overall or event-free survival.•Attaining complete molecular response pre-transplant improved event-free...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Leukemia research reports 2022-01, Vol.18, p.100352-100352, Article 100352
Hauptverfasser: Takiar, Radhika, Foucar, Charles E., Perissinotti, Anthony J., Marini, Bernard L., Benitez-Colon, Lydia, Burke, Patrick W., Bixby, Dale L.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•Duration, type and timing of TKI remains controversial for Ph+ ALL.•Pre-transplant dasatinib/imatinib led to favorable outcomes among Ph+ ALL patients.•Type of pre-transplant TKI did not impact overall or event-free survival.•Attaining complete molecular response pre-transplant improved event-free survival. Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) has been associated with a worse prognosis compared to Ph negative ALL. Tyrosine kinase inhibitor (TKI) therapy has led to an improvement in response rates and survival, thus becoming a critical component of therapy. We performed a retrospective cohort study of Ph+ ALL patients treated at the University of Michigan who received TKI therapy pre- and post-allogeneic hematopoietic stem cell transplant (HSCT) from April 2007 to November 2019. The study included 40 patients with Ph+ ALL (47.5% female) with a median age of 54 (24-69) years. Median event-free survival (EFS) was not reached, with a 5-year EFS of 61%. Median overall survival (OS) was not reached, with a 5-year OS of 71%. There was no difference in 2-year EFS or OS for patients on pre-transplant imatinib or dasatinib (p = 0.16, 0.09, respectively), though definitive conclusions are challenging as post-transplant TKI therapy was variable. The incidence of any grade acute graft-versus-host disease (GVHD) was 62.5% (25/40) and any grade chronic GVHD was 77.5% (31/40). Complete molecular remission (CMR) was achieved in 57.5% of patients pre-transplant with no significant difference when stratified by induction TKI (p = 1). Achievement of CMR pre-HSCT showed a trend towards improved 2-year EFS (p=0.0198) but did not significantly change 2-year OS (p = 1). Patients receiving 1st and 2nd generation TKIs pre- and post-HSCT seem to have favorable outcomes, although type of TKI (pre-HSCT) did not significantly impact EFS or OS. In addition, attaining a CMR pre-transplant improved EFS, but did not change OS.
ISSN:2213-0489
2213-0489
DOI:10.1016/j.lrr.2022.100352